Journal article
Does self monitoring of blood glucose as opposed to urinalysis provide additional benefit in patients newly diagnosed with type 2 diabetes receiving structured education? The DESMOND SMBG randomised controlled trial protocol
Helen M Dallosso, Helen C Eborall, Heather Daly, Lorraine Martin-Stacey, Jane Speight, Kathryn Realf, Marian E Carey, Michael J Campbell, Simon Dixon, Kamlesh Khunti, Melanie J Davies, Simon Heller
BMC Family Practice | BMC | Published : 2012
Abstract
BACKGROUND: The benefit of self-monitoring of blood glucose (SMBG) in people with type 2 diabetes on diet or oral agents other than sulphonylureas remains uncertain. Trials of interventions incorporating education about self-monitoring of blood glucose have reported mixed results. A recent systematic review concluded that SMBG was not cost-effective. However, what was unclear was whether a cheaper method of self-monitoring (such as urine glucose monitoring) could produce comparable benefit and patient acceptability for less cost. METHODS/DESIGN: The DESMOND SMBG trial is comparing two monitoring strategies (blood glucose monitoring and urine testing) over 18 months when incorporated into a c..
View full abstractGrants
Awarded by Diabetes UK
Awarded by National Institute for Health Research
Funding Acknowledgements
The authors would like to acknowledge all the practice nurses for referring participants and collecting follow-up data and also the 23 DESMOND Educators who delivered the study intervention. The authors are grateful to all of the people with T2DM who are participating in the trial. We thank Emma Pitchforth for designing the qualitative sub-studies. The DESMOND SMBG study was funded by a grant from Diabetes UK [BDA RD05/3253].JS is a member of the Australian Accu-Chek Advisory Board (Roche Diagnostics) and has previously been the recipient of an unrestricted educational grant, funding for conference travel and consultancy fees. Her research centre has also received sponsorship from Roche Diagnostics and Abbott Diabetes Care toward the costs of hosting the 2011 Symposium for Behavioural Research in Diabetes (Perth, Sept 2011).MJD has acted as consultant, advisory board member and speaker for Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme and Roche, and as a speaker for Servier. She has received grants in support of investigator and investigator initiated trials from Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Pfizer, Merck Sharp & Dohme, GlaxoSmithKline and Servier.KK has acted as a consultant and speaker for Novartis, Novo Nordisk, Sanofi-Aventis, Lilly and Merck Sharp & Dohme. He has received grants in support of investigator and investigator initiated trials from Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Pfizer, Boehringer Ingelheim and Merck Sharp & Dohme. SRH has served on advisory boards and given talks at meetings on behalf of Abbot and Lifescan for which his institution has received fees. He also chaired the NHS Diabetes working group which reported on SMBG in Type 2 diabetes in 2009.